All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

ECLIPSE 2 is one of three trials in Vir Biotechnology’s registrational ECLIPSE program for CHD, which was initiated in March 2025.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

Java defies the hype cycle, thriving at 30 with unmatched enterprise trust, modern AI integration, and a vibrant, global developer community.

Eclipse IDE is a widely-used open-source integrated development environment for Java and other programming languages. This offline activation guide enables full use of Eclipse’s professional features ...

Jakarta EE, a working group hosted by the Eclipse Foundation, today announced the general availability of the Jakarta EE 11 Platform, the latest version of its enterprise Java platform. The new ...

Get insights into Vir Biotechnology's Q1 2025 earnings call, including ECLIPSE Phase III trial progress, oncology updates, and financial highlights.

HENDERSON, Nev., May 7, 2025 /PRNewswire/ -- AEROCOR, LLC is proud to announce its official partnership with the Eclipse Jet Owners and Pilots Association (EJOPA) to deliver a Flight Operational ...